Abstract | BACKGROUND: METHODS: Our analytic cohort included 20,962 participants in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) who had SPGI level measured. Of these, 1663 (7.9%) subjects had low SPGI levels (<25 microg/l) and were invited for gastroscopy which was completed in 1059 (63.7%) participants. Atrophic gastritis was histologically confirmed in 1006 (95.0%) subjects. We used Cox proportional hazards regression to calculate the hazard ratios (HR) and 95% confidence intervals (CI) for pancreatic cancer. RESULTS: During follow-up of up to 16.3 years (mean=10.8 years; 226,325 person-years), 227 incident pancreatic cancers were diagnosed. The incidence rates were 9.9, 11.3, and 12.7 per 10,000 person-years of follow-up for participants with normal pepsinogen level (> or = 25 microg/l), low pepsinogen level and histologically confirmed atrophic gastritis, respectively. Compared to subjects with normal pepsinogen levels, there was no statistically significant increased risk of pancreatic cancer among subjects with low pepsinogen level (adjusted HR=1.01; 95% CI: 0.63-1.62) or those with histologically confirmed atrophic gastritis (adjusted HR=1.13; 95% CI: 0.66-1.95). CONCLUSIONS:
|
Authors | Adeyinka O Laiyemo, Farin Kamangar, Pamela M Marcus, Philip R Taylor, Jarmo Virtamo, Demetrius Albanes, Rachael Z Stolzenberg-Solomon |
Journal | Cancer epidemiology
(Cancer Epidemiol)
Vol. 33
Issue 5
Pg. 368-73
(Nov 2009)
ISSN: 1877-783X [Electronic] Netherlands |
PMID | 19800305
(Publication Type: Journal Article, Research Support, N.I.H., Intramural)
|
Chemical References |
- Biomarkers, Tumor
- Pepsinogen A
|
Topics |
- Aged
- Biomarkers, Tumor
(blood)
- Cohort Studies
- Gastritis, Atrophic
(blood)
- Humans
- Incidence
- Male
- Middle Aged
- Pancreatic Neoplasms
(blood, epidemiology)
- Pepsinogen A
(blood)
- Precancerous Conditions
(blood)
- Randomized Controlled Trials as Topic
- Risk Factors
|